---
title: "ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.941 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265940155.md"
datetime: "2025-11-14T13:24:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265940155.md)
  - [en](https://longbridge.com/en/news/265940155.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265940155.md)
generator: "portal-rs"
---

# ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 1.941 K

Revenue: As of FY2025 Q3, the actual value is USD 1.941 K.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

EBIT: As of FY2025 Q3, the actual value is USD 334.56 K.

### Segment Revenue

-   **Net Revenue**: For the three and nine months ended September 30, 2025, net revenue was $1,941, with no revenue reported for the same periods in 2024.

### Operational Metrics

-   **Gross Profit**: For the three and nine months ended September 30, 2025, gross profit was $884, with no gross profit reported for the same periods in 2024.
-   **Operating Expenses**: Total operating expenses for the three months ended September 30, 2025, were $1,146,381, compared to $215,256 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $17,502,751, compared to $543,149 for the same period in 2024.
-   **Net Loss**: For the three months ended September 30, 2025, net loss was - $1,850,493, compared to - $216,269 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $19,773,114, compared to - $544,162 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the nine months ended September 30, 2025, net cash used in operating activities was - $3,995,648, compared to - $744,755 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: For the nine months ended September 30, 2025, net cash provided by financing activities was $5,940,286, compared to $750,122 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Aspire Biopharma Holdings, Inc. plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company intends to submit a section 505(b)(2) NDA for its high-dose aspirin product following positive clinical trial results, with plans to seek FDA 505(b)(2) Fast Track designation in the first quarter of 2026.
-   **Non-Core Business**: Aspire is exploring licensing possibilities for its sublingual melatonin sleep-aid product and has developed formulations for sublingually administered vitamins and semaglutide. The company is also developing caffeine products and considering formulations for other drug classes.

### Related Stocks

- [ASBPW.US](https://longbridge.com/en/quote/ASBPW.US.md)

## Related News & Research

- [Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead](https://longbridge.com/en/news/298782816.md)
- [Reliance (RS) Heads To Jefferies Conference Following Demand Led Fair Value Debate](https://longbridge.com/en/news/298815052.md)
- [Estée Lauder Companies (EL) Leadership Reset Puts Its Valuation Narrative To The Test](https://longbridge.com/en/news/298814962.md)
- [What Callaway Golf Stock's Weak Demand Means For Shareholders](https://longbridge.com/en/news/298808210.md)
- [Can PBF Energy (PBF) Justify Its Price Following Blowout Earnings And A New Dividend?](https://longbridge.com/en/news/298807882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**